Business Context and Reporting Period
Daré Bioscience, Inc. (DARE) filed a Form 8-K Current Report on May 14, 2026, regarding the completion of closings for a previously announced Regulation A offering. The company is incorporated in Delaware and its common stock trades on the Nasdaq Capital Market.
Key Financial Metrics and Transaction Details
This filing reports a specific capital raise event rather than periodic financial performance metrics such as revenue or operating cash flow. The transaction details are as follows:
- Offering Type: Regulation A offering of Investor Units.
- Units Issued: 50,000 Investor Units.
- Components per Unit: One share of Series A Convertible Preferred Stock and two warrants to purchase one share of common stock each.
- Offering Price: $5.00 per Investor Unit.
- Total Capital Raised: $250,000 (50,000 units x $5.00).
- Securities Issued: 50,000 shares of Series A Preferred Stock and warrants to purchase up to 100,000 shares of common stock.
The filing text does not provide clear values for revenue, profit, margins, debt, or liquidity positions outside of this specific transaction.
Material Changes
The material change reported is the issuance of new equity securities. The company closed the sale of 50,000 Investor Units on May 14, 2026, pursuant to an offering statement on Form 1-A qualified by the SEC on April 1, 2026. This represents a partial closing of an offering authorized for up to 4,854,000 units.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future outlook, or specific risk factors beyond the standard incorporation by reference to previous filings (specifically the Form 8-K filed on January 29, 2026) regarding the terms of conversion and exercise of the Series A Preferred Stock and Investor Warrants.
Investor Verification Checklist
- Verify the total number of Investor Units sold to date against the maximum authorized offering size of 4,854,000 units.
- Review the specific conversion terms and exercise prices for the Series A Preferred Stock and Investor Warrants in the January 29, 2026, Form 8-K.
- Confirm the use of proceeds from the $250,000 raised in this closing as disclosed in the offering circular.
- Check for any subsequent filings regarding the remaining unsold portion of the Regulation A offering.